FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Effects of live-online, group mindfulness training on opioid use and anxiety during buprenorphine treatment: A comparative effectiveness RCT. PMID 38135210 · Contemp Clin Trials · 2024-Feb Record is a protocol for a randomized trial in opioid use disorder, not oncology. The abstract explicitly states 'Data collection is projected to end by September 2023, and we expect publication of results in 2024', confirming it is a protocol without results. The primary outcome is biochemically confirmed abstinence, not a time-to-event endpoint like OS, PFS, DFS, etc. While the trial involves buprenorphine (a drug), it is not an oncology study. The deterministic review correctly identified the absence of a time-to-event signal. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer - An NRG/GOG study. PMID 38134754 · Gynecol Oncol · 2024-Feb The abstract describes a secondary/prognostic analysis of CA-125 levels from a Phase III trial cohort. While it includes time-to-event efficacy data (RFS, OS with HRs), the primary purpose is to evaluate a biomarker's prognostic significance, not to report the primary efficacy comparison of the randomized trial's drug intervention. Randomization is not explicitly confirmed in the text. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-term follow-up results of a pilot study for nodular basal cell carcinoma with PDT using partial home treatment protocol. PMID 38103584 · Photodiagnosis Photodyn Ther · 2024-Feb The study is explicitly described as a 'pilot study' and does not establish Phase III or Phase II/III status. While it reports a time-to-event endpoint (recurrence-free survival) and is a randomized trial, the intervention is photodynamic therapy (a device/procedure using light activation), not a drug-containing intervention as required by the criteria. The drug (methyl aminolevulinate cream) is a photosensitizer used as part of the procedure, but the primary therapeutic intervention is the light irradiation (including a portable device used at home), making this a non-drug-only intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial. PMID 38097741 · Br J Cancer · 2024-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Treatment interval in curative treatment of colon cancer, does it impact (cancer free) survival? A non-inferiority analysis. PMID 38087040 · Br J Cancer · 2024-Feb Study is a retrospective, non-randomized, non-inferiority analysis of treatment interval timing in colon cancer surgery. It does not meet the core criteria of being a randomized trial with a drug intervention and a definitive trial phase. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Development of osteonecrosis and improved survival in B-ALL: results of Children's Oncology Group Trial AALL0232. PMID 38062123 · Leukemia · 2024-Feb The study is from a randomized trial with drug interventions and time-to-event endpoints, but the abstract presents results primarily from a secondary analysis (osteonecrosis incidence and its association with survival) rather than the primary trial efficacy results. The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the metadata. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A Randomized Clinical Trial Evaluating Indigo Carmine as a Visualization Aid for Evaluating Ureteral Patency. PMID 38061609 · Urology · 2024-Feb Study is an oncology-related (urinary bladder neoplasms in mesh) randomized trial with a drug intervention, but it is not a Phase III or definitive Phase II/III trial, and its primary efficacy endpoint is not a time-to-event survival or progression metric. It evaluates a visualization aid for ureteral patency, not a therapeutic efficacy endpoint for cancer. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Endoscopic ultrasonography-guided gastroenterostomy versus uncovered duodenal metal stenting for unresectable malignant gastric outlet obstruction (DRA-GOO): a multicentre randomised controlled trial. PMID 38061378 · Lancet Gastroenterol Hepatol · 2024-Feb 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Randomized adaptive selection trial of cryotherapy, compression therapy, and placebo to prevent taxane-induced peripheral neuropathy in patients with breast cancer. PMID 38060077 · Breast Cancer Res Treat · 2024-Feb This is a randomized Phase IIB adaptive selection trial with a drug-containing taxane intervention and an original result report. However, it is not a Phase III trial, and its primary endpoint is a binary toxicity outcome at 12 weeks (FACT-NTX decrease), not a time-to-event efficacy endpoint like OS, PFS, or DFS, and no Kaplan-Meier or HR analysis is reported for such an endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes. PMID 38060001 · Ann Hematol · 2024-Feb 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Hitting the Target: Developing High-quality Evidence for Proton Beam Therapy Through Randomised Controlled Trials. PMID 38042671 · Clin Oncol (R Coll Radiol) · 2024-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer. PMID 38019444 · Breast Cancer Res Treat · 2024-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Long-term outcomes of neoadjuvant immunotherapy plus chemotherapy in patients with early-stage triple-negative breast cancer: an extracted individual patient data and trial-level meta-analysis. PMID 38012381 · Br J Cancer · 2024-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Study Protocol of a Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in COVID-19 Patients with Comorbidities. PMID 38010606 · Adv Ther · 2024-Feb 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First-Line Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer. PMID 38010260 · Clin Pharmacol Ther · 2024-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Nomogram Update to Predict the High Genomic Risk Breast Cancer by Different Races. PMID 38007348 · Clin Breast Cancer · 2024-Feb The record is a study developing a nomogram to predict a genomic recurrence score (RS) from clinicopathologic variables in breast cancer. While it is oncology, human, and uses randomization for cohort splitting, it lacks a drug-containing intervention and does not report a primary/key secondary time-to-event efficacy endpoint. It is a diagnostic/prognostic model validation study, not a therapeutic trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial. PMID 37996507 · Br J Cancer · 2024-Feb The record is a final results report of a randomized Phase III trial (implied by definitive comparison and efficacy focus) in human oncology with a drug intervention and primary/time-to-event endpoints. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | confirmed 1 Figure · 4 Panel · risk visible |
| Talking, not training, increased the accuracy of physicians' diagnosis of their patients' preferences for colon cancer screening. PMID 37976668 · Patient Educ Couns · 2024-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial). PMID 37973958 · Br J Cancer · 2024-Feb The study is a randomized, phase III trial in oncology patients with a drug intervention and provides original results. However, the primary and key reported endpoints are complete response rates and other categorical antiemetic efficacy outcomes (e.g., total control rates, nausea, appetite loss). There is no signal of a primary/key secondary time-to-event efficacy endpoint (e.g., overall survival, progression-free survival, disease-free survival, event-free survival, recurrence-free survival, time to progression), nor any mention of Kaplan-Meier estimates or hazard ratios. Therefore, it does not meet the core requirement for a time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and offers alternatives for novel assessment of clinical trials. PMID 37955764 · Breast Cancer Res Treat · 2024-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States. PMID 37919137 · Clin Lymphoma Myeloma Leuk · 2024-Feb This is a retrospective chart review of real-world data, not a randomized controlled trial. It reports outcomes from a non-randomized comparison of brentuximab vedotin versus other standard therapies. The ALCANZA trial mentioned is referenced but not reported on. Therefore, it does not meet the criteria for an original Phase III or II/III randomized trial with a drug-containing intervention and a primary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparative study between mitomycin C versus Bacillus Calmette-Guérin (BCG) in high-risk non-muscle-invasive bladder cancer. PMID 37905506 · Urologia · 2024-Feb The record is a randomized, oncology, human trial with a drug intervention and a time-to-event efficacy endpoint. However, the required phase (Phase III/IIIb or Phase II/III) is not explicitly established in the provided metadata or abstract. Therefore, eligibility cannot be confirmed. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparison of PET/CT-based eligibility according to VISION and TheraP trial criteria in end-stage prostate cancer patients undergoing radioligand therapy. PMID 37891376 · Ann Nucl Med · 2024-Feb This is a retrospective analysis of patient cohorts from two existing trials (VISION, TheraP) to compare eligibility criteria. It is not a primary report of a Phase III/IIIb or Phase II/III randomized trial with a drug intervention. The study itself is observational (retrospective cohort), not randomized, and does not report original trial results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of Pulmonary Rehabilitation Exercise on Lung Volume and Respiratory Muscle Recovery in Lung Cancer Patients Undergoing Lobectomy. PMID 37883752 · Altern Ther Health Med · 2024-Feb The study is a randomized, oncology, human trial with an original result. However, it fails eligibility because: 1) The trial phase is not specified and the design (small, single-center, postoperative rehab) is not indicative of a definitive Phase III/IIIb or Phase II/III trial. 2) The primary efficacy endpoints are pulmonary function metrics (FVC, FEV1, etc.) and functional capacity (6MWT), which are not the specified time-to-event endpoints (OS, PFS, DFS, etc.). 3) The intervention involves albuterol (a bronchodilator) combined with exercise, not a cytotoxic or targeted anti-cancer drug regimen. Therefore, it does not meet the core eligibility criteria for the cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Novel Digital Educational Strategy Improves Treatment Adherence and Quality of Life in Patients with Multiple Myeloma. PMID 37875743 · J Cancer Educ · 2024-Feb The study is an oncology RCT in humans reporting original results, but it is ineligible because it lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, TTP, with Kaplan-Meier or HR). The intervention is a non-drug educational strategy, and the phase is not explicitly stated as definitive (Phase III/IIIb or Phase II/III). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Texture and Color Enhancement Imaging Improves Colonic Adenoma Detection: A Multicenter Randomized Controlled Trial. PMID 37839498 · Gastroenterology · 2024-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study. PMID 37797733 · J Thorac Oncol · 2024-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Individualized Use of 6-Mercaptopurine in Chinese Children with ALL: A Multicenter Randomized Controlled Trial. PMID 37753808 · Clin Pharmacol Ther · 2024-Feb The trial is an original randomized study in oncology with a drug intervention. However, it fails the eligibility criteria because: (1) the Phase III/IIIb or Phase II/III status is not established; (2) the primary efficacy endpoint is a toxicity/incidence endpoint, not time-to-event; and (3) while event-free survival is a secondary endpoint, the abstract provides no time-to-event results (e.g., KM curves, HR) for it. Therefore, the record does not meet the requirement of having a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma. PMID 37671748 · Future Oncol · 2024-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Long-Term Efficacy and Safety of Canakinumab in Patients With Tumor Necrosis Factor Receptor-Associated Periodic Syndrome: Results From a Phase III Trial. PMID 37668289 · Arthritis Rheumatol · 2024-Feb The study is a Phase III trial of canakinumab in TRAPS, a non-oncologic autoinflammatory disease. While it meets criteria for human, Phase III, drug intervention, and original results, it fails the oncology requirement and lacks a specified time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| No Observed Difference in Inflammatory and Coagulation Markers Following Diets Rich in n-6 Polyunsaturated Fat vs Monounsaturated Fat in Adults With Untreated Hypercholesterolemia: A Randomized Trial. PMID 37619782 · J Acad Nutr Diet · 2024-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy. PMID 37604702 · BJU Int · 2024-Feb 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Transcatheter arterial chemoembolization using CalliSpheres beads loaded with arsenic trioxide for unresectable large or huge hepatocellular carcinoma: a prospective study. PMID 37581654 · Eur Radiol · 2024-Feb The study is a randomized trial in human oncology (HCC) with a primary time-to-event endpoint (PFS) and a secondary time-to-event endpoint (OS), comparing a drug intervention (CalliSpheres beads loaded with arsenic trioxide) to a control (conventional TACE), and reports formal comparative results. However, the phase (III/IIIb or II/III) is not explicitly established in the provided record, preventing full eligibility confirmation. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Peritoneal Flap for Lymphocele Prophylaxis Following Robotic-assisted Radical Prostatectomy with Lymph Node Dissection: The Randomised Controlled Phase 3 PELYCAN Trial. PMID 37543465 · Eur Urol Oncol · 2024-Feb 干预为非药物单独策略,未满足药物干预要求。 |
H
L
B
|
旧查询独有 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Combination of Compound Kushen injection with first-line treatment versus first-line treatment alone for advanced colorectal cancer: a study protocol for a multicenter, openlabel, randomized controlled trial. PMID 39741233 · BMC Complement Med Ther · 2024-Dec-31 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Gastric partitioning versus gastrojejunostomy for gastric outlet obstruction due to unresectable gastric cancer: randomized clinical trial. PMID 39835447 · BJS Open · 2024-Dec-30 The trial is an oncology, human, randomized controlled trial with an original result. However, it does not meet the required eligibility criteria. The intervention is surgical, not a drug-containing intervention. Furthermore, the study does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR); survival is mentioned but no time-to-event data are provided. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Proton therapy versus conventional radiotherapy for the treatment of cavernous sinus benign meningioma, a randomized controlled phase III study protocol (COG-PROTON-01). PMID 39736544 · BMC Cancer · 2024-Dec-30 方案论文未报告临床试验结果。 |
H
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| The Win Ratio Approach in Bayesian Monitoring for Two-Arm Phase II Clinical Trial Designs With Multiple Time-To-Event Endpoints. PMID 39582325 · Stat Med · 2024-Dec-30 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The Mucosal Protection in the Treatment of Erosive Reflux Esophagitis: Mechanisms for Restoring Epithelial Permeability. A Randomized Clinical Trial. PMID 39733305 · J Gastrointestin Liver Dis · 2024-Dec-28 The study is a randomized trial of drug intervention for erosive gastroesophageal reflux disease (GERD), not a human malignant neoplasm. It does not report a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) or Kaplan-Meier/HR analysis. Therefore, it is ineligible for the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Post-Diagnostic Aspirin Use in Breast Cancer Treatment: A Systematic Review and Meta-Analysis of Survival Outcomes with Trial Sequential Analysis Validation. PMID 39795572 · Diagnostics (Basel) · 2024-Dec-27 The record is a systematic review and meta-analysis, not an original formal-result report of a randomized trial. It does not meet the core inclusion criterion of being an original report of a Phase III/IIIb or Phase II/III randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Heidelberg Decision Aid for Patients With Lung Cancer (HELP)—Findings of a Randomized Controlled Trial. PMID 39635949 · Dtsch Arztebl Int · 2024-Dec-27 The study is a randomized controlled trial in oncology (lung cancer) with original results, but it evaluates a non-drug intervention (decision aid) and uses patient-reported decisional conflict as the primary endpoint, not a time-to-event efficacy endpoint like OS or PFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of electroacupuncture versus sham electroacupuncture on postoperative ileus after laparoscopic surgery for left-sided colorectal cancer: study protocol for a multicentre, randomised, sham-controlled trial. PMID 39725420 · BMJ Open · 2024-Dec-26 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC. PMID 39721752 · J Immunother Cancer · 2024-Dec-25 While the record is from an oncology, human, randomized, Phase III trial with a drug intervention and original results, it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier curves or hazard ratios. The analysis centers on T-cell receptor sequencing as a biomarker for response and toxicity. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Application of indocyanine green-human serum albumin complex in fluorescence image-guided laparoscopic anatomical liver resection: study protocol for a randomized controlled trial. PMID 39710697 · Trials · 2024-Dec-23 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Randomized Controlled Trial of a Text-Based Smokeless Tobacco Cessation Intervention for Rural and Medically Underserved Communities. PMID 39030750 · Nicotine Tob Res · 2024-Dec-23 The study is a randomized controlled trial for smokeless tobacco cessation, which is a behavioral intervention (text-based support and education booklet) for a non-cancer (tobacco cessation) condition. It does not involve a drug intervention for a human malignant neoplasm. Furthermore, the primary endpoint is point prevalence abstinence (a binary outcome at a fixed time point), not a time-to-event endpoint like OS, PFS, DFS, etc., and no Kaplan-Meier or HR is reported. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancer. PMID 39806715 · BMJ Open · 2024-Dec-22 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) trial: study protocol for a multicentre, double-blinded, placebo-controlled, phase IIa trial. PMID 39773995 · BMJ Open · 2024-Dec-22 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Prognostic value of metabolic tumor volume on [18F]FDG PET/CT in addition to the TNM classification system of locally advanced non-small cell lung cancer. PMID 39709461 · Cancer Imaging · 2024-Dec-21 The record is a retrospective prognostic biomarker analysis of metabolic tumor volume (MTV) using imaging from a randomized trial (PETPLAN). While it involves human oncology patients and a randomized trial, it does not meet the core eligibility criteria: it is not a report of a drug intervention study (the intervention is the imaging biomarker/analysis, not a drug), and it is a secondary prognostic analysis rather than a primary trial efficacy result. The Phase III status is not explicitly confirmed in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| PTSD Coach as an early mobile intervention to improve cancer-related anxiety and psychosocial oncology uptake in patients newly diagnosed with head and neck cancer: pilot randomized controlled trial. PMID 39709459 · Pilot Feasibility Stud · 2024-Dec-21 This is a pilot randomized controlled trial of a psychosocial mobile app intervention (PTSD Coach) for head and neck cancer patients. It does not involve a drug intervention, does not report a time-to-event efficacy endpoint (OS, PFS, DFS, etc.), and is a feasibility/pilot study rather than a definitive Phase III trial with efficacy results. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Impact of mindfulness-based tri-modal prehabilitation on functional recovery and selected surgical outcomes of patients with colorectal cancer admitted to surgical hospital wards: the first international randomised control trial for mindfulness-based tri-modal prehabilitation. PMID 39806718 · BMJ Open · 2024-Dec-20 This is a clinical trial protocol for a randomized controlled trial in oncology patients, but it is excluded because it is not a Phase III or definitive trial, does not involve a drug intervention, does not report time-to-event efficacy endpoints, and does not present results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |